Table 3.

Utility input data

Description	Age	General population		Mutation carrier	p value f	Method
		Base case	Sensitivity analysis e	Mean values
DF, age-specific [42]	30–39	0.901				EQ-5D
	40–49	0.871
	50–59	0.842
	60–69	0.823
	70–79	0.790
	≥ 80	0.736
BC a [43]		0.637	± 20%			Meta-regression analysis
MBC b [43]		0.533	± 20%			Meta-regression analysis
OC c [99]		0.410	± 20%			Visual analogue scale
IS d [88]		0.960	± 5%	1.00	< 0.01	Time trade-off
PBM [88]		0.880	± 10%	0.88	< 0.11	Time trade-off
PBSO [88]		0.900	± 10%	0.95	< 0.01	Time trade-off
PBM & PBSO [19]		0.790	± 10%	0.84		Time trade-off
CP [88]		0.900	± 5%	0.95	< 0.01	Time trade-off

^aUtility value of BC was derived using the constant early BC, mastectomy & reconstruction, chemotherapy non-specific, public community, EQ-5D (model 2)

^bUtility value of MBC was derived using the constant MBC, chemotherapy non-specified, response non-specified, public community, EQ-5D (model 2)

^cUtility value of OC: the following values were assumed over five years (a recurrence was assumed to occur within about 2 years after primary OC diagnosis [31] and overall survival after recurrence is about 30 months [100]) and averaged [99]: 0.56 (for the 1./2. year (newly diagnosed ovarian cancer—chemotherapy/grades 1–2 toxicity), 0.43 (for the 3./4. year (recurrent ovarian cancer—responding to chemotherapy/grades 1–2 toxicity); 0.08 (5. year (end stage)) resulting in an average calculated utility value of 0.41

^dIntensified surveillance: utility value of annual MRI was used (annual mammography: 0.97)

^eEstimated variation

^f Probability that there is no difference in the utility value between the general population and mutation carriers

Abbreviations: DF (disease-free), BC (breast cancer), MBC (metastatic breast cancer), OC (ovarian cancer), IS (intensified surveillance) PBM (prophylactic bilateral mastectomy), PBSO (prophylactic bilateral salpingo-oophorectomy), CP (chemoprevention)